» Articles » PMID: 17106243

Identification of Fibroblast Heterogeneity in the Tumor Microenvironment

Overview
Specialties Oncology
Pharmacology
Date 2006 Nov 16
PMID 17106243
Citations 375
Authors
Affiliations
Soon will be listed here.
Abstract

Tumors are unorganized organs that contain many different cell types. In the recent years, many studies have reported that primary tumors contain fibroblasts/myofibroblasts (carcinoma-associated fibroblasts), mesenchymal cells such as pericytes/mural cells and other vascular smooth muscle cells. Several different markers are used routinely to identify carcinoma-associated fibroblasts (CAFs) such as alpha-smooth muscle actin (alpha-SMA), vimentin, S100A4 protein/fibroblast specific protein-1 (FSP1) and type I collagen. Likewise markers such as platelet derived growth factor receptor-beta (PDGFRbeta) and NG2 chondroitin sulfate proteoglycan (NG2) are used to identify mesenchymal cells such as pericytes and other vasculature associated smooth muscle cells. It is still unknown whether these markers overlap with each other or identify a unique population of cells within the tumor microenvironment. Therefore in the present study we utilized two different mouse models of cancer, the Rip1Tag2 mice that develop progressive pancreatic cancer and an orthotopic 4T1 breast cancer model, to study the overlap between six different mesenchymal markers commonly used in mouse cancer research. Our study demonstrates that among all the markers, S100A4/FSP1 identifies a unique population of fibroblasts with minimal overlap with markers for alphaSMA, PDGFRbeta and NG2. Vimentin and type I collagen are not specific markers for fibroblasts in these tumors. alphaSMA, PDGFRbeta and NG2 significantly overlap with each other in identifying a mixed population of fibroblasts (activated or resting), myofibroblasts, pericytes and vascular smooth muscle cells. Collectively, this study demonstrates that tumor microenvironment associated fibroblasts are a heterogeneous population and thus, the use of alphaSMA or vimentin as the only markers will not identify all the CAFs.

Citing Articles

The multi-faceted immune modulatory role of S100A4 in cancer and chronic inflammatory disease.

Wong T, Kang R, Yun K Front Immunol. 2025; 16:1525567.

PMID: 40078995 PMC: 11897520. DOI: 10.3389/fimmu.2025.1525567.


Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.

Cao Z, Quazi S, Arora S, Osellame L, Burvenich I, Janes P J Biomed Sci. 2025; 32(1):7.

PMID: 39780187 PMC: 11715488. DOI: 10.1186/s12929-024-01099-2.


Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer.

Yan Y, Sun D, Hu J, Chen Y, Sun L, Yu H Nat Genet. 2024; 57(1):126-139.

PMID: 39658657 DOI: 10.1038/s41588-024-01998-y.


Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine.

Cassani M, Fernandes S, Pagliari S, Cavalieri F, Caruso F, Forte G Adv Sci (Weinh). 2024; 12(2):e2409898.

PMID: 39629891 PMC: 11727388. DOI: 10.1002/advs.202409898.


Age-Related ECM Stiffness Mediates TRAIL Activation in Muscle Stem Cell Differentiation.

Alakhdar A, Sivakumar S, Kopchak R, Hunter A, Ambrosio F, Washburn N Adv Biol (Weinh). 2024; 8(12):e2400334.

PMID: 39601528 PMC: 11889993. DOI: 10.1002/adbi.202400334.